(+-)-13-氮杂前列腺烷酸 | 71629-07-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (+-)-13-氮杂前列腺烷酸
• 英文名称: 13-Azaprostanoic acid
• 英文别名: 7-[(1S,2S)-2-(heptylamino)cyclopentyl]heptanoic acid
• CAS: 71629-07-7
• 化学式: C₁₉H₃₇NO₂
• 分子量: 311.5
• InChiKey: RZZNGDIYQSCFGK-ROUUACIJSA-N

物化性质

• 沸点：
  444.3±18.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Thromboxane antagonists for use in the treatment of hormone-dependent neoplasias
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0336522A2

  公开（公告）日：1989-10-11

  Compounds having thromboxane antagonist activity are of use in the treatment of hormone-dependent neoplasias, for example oestrogen-dependent neoplasias.

  具有血栓素拮抗剂活性的化合物可用于治疗激素依赖性肿瘤，例如雌激素依赖性肿瘤。
• Use of TP-receptor antagonists to modify the action of myofibroblasts
  申请人：GLAXO GROUP LIMITED

  公开号：EP0337739A2

  公开（公告）日：1989-10-18

  The use is described of TP-receptor antagonists in the manufacture of medicaments for the treatment or prophylaxis of conditions caused or exacerbated by myofibroblast cell contraction.

  描述了 TP 受体拮抗剂在制造治疗或预防由肌成纤维细胞收缩引起或加剧的疾病的药物中的用途。
• Dietary emulsion formulations and methods for using the same
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10328045B2

  公开（公告）日：2019-06-25

  Disclosed herein is a formulation that can take the form of an emulsion which contains total enteral or parenteral nutrition for a recipient subject. The formulation includes as the sole fat components: (i) medium chain triglycerides; and (ii) very long chain fatty acids selected from (a) very long chain omega-3 polyunsaturated fatty acids; and (b) docosahexaenoic acid and arachidonic acid in a ratio of about 10:1 (v/v or w/w) to about 2000:1 (v/v or w/w). The sole fat components provide about 10% to about 90% total calories of the formulation, and the medium chain triglycerides provide about 25%-95% total fat calories of the formulation. Methods and kits for utilizing the formulation and for treating various disorders and diseases that involve an inflammatory response are also disclosed.

  本文公开了一种制剂，该制剂可采用乳剂的形式，其中含有供受试者使用的全部肠内或肠外营养。该制剂包括作为唯一脂肪成分的(i) 中链甘油三酯；和 (ii) 选自 (a) 超长链欧米伽-3 多不饱和脂肪酸；和 (b) 二十二碳六烯酸和花生四烯酸的超长链脂肪酸，其比例约为 10:1 (v/v 或 w/w)至约 2000:1 (v/v 或 w/w)。唯一的脂肪成分提供配方中约 10%至约 90%的总热量，中链甘油三酯提供配方中约 25%至 95%的总脂肪热量。此外，还公开了利用该制剂和治疗涉及炎症反应的各种紊乱和疾病的方法和试剂盒。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。
• THROMBOXANE ANTAGONISTS IN THE TREATMENT OF HORMONE-DEPENDENT NEOPLASIAS
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0208755A1

  公开（公告）日：1987-01-21